AI-generated summary
The authors report a randomized, double-blind, placebo-controlled trial of 660 nm LED photobiomodulation in 42 patients after mandibular third molar extraction. Early benefits on days 2 and 4 were reported for mouth opening, pain and analgesic use, with no significant differences in oedema or quality of life.
- Participants
- 42
- Who or what was studied
- Adult patients undergoing mandibular third molar extraction, allocated to an active LED group (n = 21) or a placebo group (n = 21)
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract does not state how the trial's sample size and certainty of evidence affect the findings, and no long-term follow-up beyond postoperative day 7 is reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Photobiomodulation, Visual analogue scale, Placebo-controlled. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.